What These Medications Actually Do
GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) work primarily by suppressing appetite and slowing gastric emptying, producing a large, sustained calorie deficit with minimal conscious restriction required. In the major trials, that's translated into substantial average weight loss — roughly 15% of body weight with semaglutide and over 20% with tirzepatide over about 18 months. This is a genuinely significant tool, and it's changed obesity treatment. It comes with a tradeoff that gets far less attention than the headline weight-loss numbers.
The Part That Gets Left Out: Lean Mass Loss
Weight lost on these medications isn't all fat. A review of body composition data across the major trials (Neeland, Linge & Birkenfeld, Diabetes, Obesity and Metabolism, 2024) found lean mass typically accounts for roughly 25-40% of total weight lost — in the same general range as what's seen with calorie restriction alone, but a substantial absolute amount given how much total weight these medications produce. A DEXA substudy of the semaglutide STEP 1 trial found lean mass made up about 40% of the weight lost; a DEXA substudy of the tirzepatide SURMOUNT-1 trial found a broadly similar proportional pattern. Some of that lean mass is genuinely functional muscle — and losing it isn't cosmetic. It lowers resting metabolic rate, reduces strength and physical function, and in older adults specifically raises the risk of ending treatment with a “thinner but weaker” body composition rather than a healthier one.
Why Resistance Training Matters More, Not Less
This is precisely the scenario resistance training is best evidenced for: preserving muscle during a sustained calorie deficit. Unlike dieting through willpower and restriction, GLP-1 medications remove the appetite barrier to a large deficit — which makes it easier to under-eat protein and skip training without the hunger cues that would normally prompt a correction. A narrative review in Diabetes Care (Locatelli et al., 2024) makes the case directly: resistance exercise is the most evidence-supported tool available to blunt the lean mass loss seen with these medications, working through the same mechanism it uses in any calorie deficit — providing a stimulus that signals the body to preserve, rather than break down, muscle tissue even while running short on total calories.
The Evidence, Honestly Stated
It's worth being precise here: large randomized trials directly testing resistance training as an add-on to GLP-1 therapy are still catching up to how quickly these medications have been adopted — several are actively enrolling as of this writing (the LEAN-PREP and FLEX trials among them). What exists now is a strong mechanistic case built on decades of resistance-training-during-calorie-deficit research, plus consistent findings that combining structured resistance exercise with adequate protein intake meaningfully blunts fat-free mass loss in early GLP-1-plus-exercise studies, without reducing the fat loss itself. This is a case where the mechanism, the existing calorie-deficit literature, and the early combined trials all point the same direction — even before the largest dedicated trials report out.
Where to Start
If you're on or considering a GLP-1 or GIP/GLP-1 medication, the four factors consistently identified as protecting lean mass are: adequate total protein intake (see the TDEE calculator for a starting protein target), enough protein specifically per meal rather than concentrated in one sitting, structured resistance training at least 2-3 times a week, and not letting the total calorie deficit run larger than necessary given how effectively these medications already suppress appetite. None of this is a reason to avoid these medications if your physician has recommended them — it's the difference between finishing treatment with less weight and less muscle, or less weight and preserved (or improved) strength and function.